{"id":11546,"date":"2021-06-17T14:49:48","date_gmt":"2021-06-17T14:49:48","guid":{"rendered":"https:\/\/www.mymsd.ch\/de\/?page_id=11546"},"modified":"2025-11-24T20:34:04","modified_gmt":"2025-11-24T20:34:04","slug":"best-treatment-first","status":"publish","type":"page","link":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/","title":{"rendered":"Best treatment first"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1500\" height=\"611\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\" alt=\"Older woman looking thoughtful while someone places a reassuring hand on her shoulder, with bold text discussing advanced NSCLC treatment options\" class=\"wp-image-9002\" srcset=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png 1500w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png?resize=300,122 300w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png?resize=768,313 768w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png?resize=1024,417 1024w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png?resize=320,130 320w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png?resize=120,49 120w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png?resize=1400,570 1400w\" sizes=\"auto, (max-width: 1500px) 100vw, 1500px\" \/><\/figure>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\" id=\"backtop\"><img loading=\"lazy\" decoding=\"async\" width=\"572\" height=\"265\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_57_de.png\" alt=\"Infographic showing that 57 out of 100 lung cancer patients are diagnosed with metastatic disease, illustrated with a large \u201857\u2019 over lung graphics and a magnifying glass\" class=\"wp-image-9003\" srcset=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_57_de.png 572w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_57_de.png?resize=300,139 300w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_57_de.png?resize=320,148 320w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_57_de.png?resize=120,56 120w\" sizes=\"auto, (max-width: 572px) 100vw, 572px\" \/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"572\" height=\"265\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_half_de.png\" alt=\"llustration showing that more than half of patients with advanced NSCLC do not reach second-line treatment\" class=\"wp-image-9004\" srcset=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_half_de.png 572w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_half_de.png?resize=300,139 300w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_half_de.png?resize=320,148 320w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_half_de.png?resize=120,56 120w\" sizes=\"auto, (max-width: 572px) 100vw, 572px\" \/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<h2 class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--a3d90aecdb3ad94ef92b1b8d43112650\"><strong>IMMUNTHERAPIEN \u00c4NDERN DIE BEHANDLUNGSPARADIGMEN BEI PATIENTEN MIT FORTGESCHRITTENEM NSCLC<\/strong><\/h2>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<p class=\"has-text-align-justify has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--justify  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2a0cbeff9016c3a66ced68ae2f26bdcb\">Zielgerichtete Immuntherapien in Kombination mit Chemotherapie haben im Vergleich zu Chemotherapie alleine ein erh\u00f6htes Gesamt\u00fcberleben (overall survival, OS) und progressionsfreies \u00dcberleben (progression-free survival, PFS) gezeigt<sup>5<\/sup>, wobei Studien darauf hinweisen, dass Immun-Checkpoint-Inhibitoren plus Chemotherapie als&nbsp;<strong>neue Standardtherapie<\/strong>&nbsp;f\u00fcr Patienten mit metastasiertem NSCLC mit Wildtyp erachtet werden sollten.<sup>6,7<\/sup><\/p>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"520\" height=\"232\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_charts_de.png\" alt=\"Two orange arrows showing 26% lower mortality risk and 39% lower progression risk in NSCLC patients based on meta-analysis data\" class=\"wp-image-9005\" srcset=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_charts_de.png 520w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_charts_de.png?resize=300,134 300w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_charts_de.png?resize=320,143 320w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_charts_de.png?resize=120,54 120w\" sizes=\"auto, (max-width: 520px) 100vw, 520px\" \/><figcaption class=\"wp-element-caption\">Metaanalyse von 8 Studien (n=4.646) bei Patienten mit fortgeschrittenem NSCLC ohne Plattenepithel-Histologie (71 %) und NSCLC mit PlattenepithelHistologie (29 %), die im Oktober 2018 durchgef\u00fchrt wurde. Die Patienten erhielten randomisiert die Erstlinien-Chemotherapie plus einen Anti-PD-1- oder Anti-PD-L1-Checkpoint-Inhibitor im Vergleich zur Erstlinien-Chemotherapie.<sup>5<\/sup><\/figcaption><\/figure>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<section class=\"wp-block-mconnect-theme-section has-light-grey-background-color has-background sub__entry__content wp-block-mconnect-theme-section--align-full has-red-border-color\">\n\t<div class=\"mhh-mcn-container\">\n\t\t\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/players.brightcove.net\/1905768940001\/meAxH3mZK_default\/index.html?videoId=6150234385001\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"571\" height=\"349\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/campaign_BTF_vid_image.png\" alt=\"Dr. Cappuzzo, Direktor der Onkologie und H\u00e4matologie interview\" class=\"wp-image-25821\" title=\"Dr. Cappuzzo, Direktor der Onkologie und H\u00e4matologie interview\" srcset=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/campaign_BTF_vid_image.png 571w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/campaign_BTF_vid_image.png?resize=300,183 300w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/campaign_BTF_vid_image.png?resize=320,196 320w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/campaign_BTF_vid_image.png?resize=120,73 120w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/campaign_BTF_vid_image.png?resize=130,80 130w\" sizes=\"auto, (max-width: 571px) 100vw, 571px\" \/><\/a><\/figure>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image alignleft size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"603\" height=\"187\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/cappuzzo_de.png?w=603\" alt=\"Quote graphic stating \u201cDie Patienten sollten unverz\u00fcglich die beste Behandlung erhalten\u201d\" class=\"wp-image-26252\" srcset=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/cappuzzo_de.png 603w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/cappuzzo_de.png?resize=300,93 300w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/cappuzzo_de.png?resize=320,99 320w, https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/cappuzzo_de.png?resize=120,37 120w\" sizes=\"auto, (max-width: 603px) 100vw, 603px\" \/><\/figure>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c7c1dc4faba31214f8b844a53267916d\">Dr. Cappuzzo, Direktor der Onkologie und H\u00e4matologie, AUSL della Romagna-Ravenna, Italien, bespricht die Anwendung einer wirksameren Behandlung als Erstlinie und weist darauf hin, dass dies wichtig ist, insbesondere bei Patienten mit Lungenkrebs, da wir nicht sicher sein k\u00f6nnen, dass die Patienten es bis zur Zweitlinientherapie schaffen, um eine zus\u00e4tzliche Behandlung zu erhalten.<\/p>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n    <\/div>\n<\/section>\n\n\n\n<div class=\"wp-block-buttons is-horizontal is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-499968f5 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.mymsd.ch\/de\/best-treatment-first-keytruda\/#keytruda-banner\">ANMELDEN, UM MEHR ZU ERFAHREN<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\" \/>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--202e4ca3b5febc7cdde6c984e66efb30\"><strong>Fu\u00dfnoten<\/strong><\/h5>\n\n\n\n<p class=\"has-text-align-justify has-negative-1-font-size has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--justify  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--8079e617f957a865a255da8ed0b8de46\"><em><sup>*<\/sup>Patienten, die nach der platinbasierten Erstlinientherapie aufgrund von neu diagnostiziertem nicht-kleinzelligem Lungenkarzinom im Stadium IIIB\/IV in der Zeit vor der Immuntherapie (2007 bis Mitte 2013) eine Zweitlinientherapie erhielten.1 Es bestand eine signifikante Heterogenit\u00e4t bei den Studien. Die Gruppe mit niedrigem PD-L1 (1-49) wies eine signifikante Heterogenit\u00e4t (p=0,06) zwischen dem Arzneimitteltyp und der Wirksamkeit auf: die Kombination aus Chemotherapie plus Pembrolizumab zeigte einen Nutzen f\u00fcr das OS (HR, 0,56; 95-%-Kl, 0,40-0,78; P &lt; 0,00007), anders als die Studien zu Atezolizumab als Backbone (HR, 0,92; 95-%-Kl, 0,62-1,37; P &lt; 0,69).\u00a0<sup>\u00a7<\/sup>Die P-Werte waren zweiseitig und nominal<\/em><\/p>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--608f168c4d0e9f0706d9476035699156\"><strong>Abk\u00fcrzungen<\/strong><\/h5>\n\n\n\n<p class=\"has-text-align-justify has-negative-1-font-size has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--justify  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d3c7f612b24ad685b5074f597cf2b4b5\">UE: unerw\u00fcnschtes Ereignis; ALK: anaplastische Lymphom-Kinase; BICR: zentrale Befundung (blinded independent central review);<br>Kl: Konfidenzintervall; EGFR: Wachstumsfaktorrezeptor (epidermal growth factor receptor); HR: Hazard Ratio; HRQoL: gesundheitsbezogene Lebensqualit\u00e4t (health-related quality-of-life); LS: Least-Square-Mittelwert nach der HRQoL; NR: nicht erreicht (not reached); NCCN: National Comprehensive Cancer Network; NSCLC: nicht-kleinzelliges Lungenkarzinom (non-small cell lung cancer); ORR: Gesamtansprechrate (overall response rate); OS: Gesamt\u00fcberleben (overall survival); PD-L1: programmierter Todesligand 1 (programmed death-ligand 1);<br>PFS: progressionsfreies \u00dcberleben (progression-free survival); Q3W: alle 3 Wochen; QoL: Lebensqualit\u00e4t (quality of life).<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--47df5bcae2655013177101618c7bbb7e\"><strong>Quellen<\/strong><\/h5>\n\n\n\n<ol class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--89cca4c3aaaf9d9e1883f003a14e7b67 mhh-mcn-list mhh-mcn-v2-clist--ordered mhh-mcn-v2-clist--ordered-decimal\" dir=\"ltr\" lang=\"en-US\" start=\"1\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Arunachalam A, et al. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018;19:e783-e799.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Gadgeel S, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer [am 9. M\u00e4rz 2020 vor Ver\u00f6ffentlichung der Druckversion online ver\u00f6ffentlicht]. J Clin Oncol. doi:10.1200\/JC0.19.03136.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Paz-Ares L, et al. Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC: Final Analysis and Progression After the Next Line of Therapy (PFS2) in KEYNOTE-407. Poster LBA852, pr\u00e4sentiert auf dem Kongress der European Society for Medical Oncology (ESMO); 27. September \u2013 1. Oktober 2019; Barcelona, Spanien.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    National Cancer Institute. Cancer Stat Facts: Lunch and Bronchus Cancer, 2020.<br>Verf\u00fcgbar unter:\u00a0<a href=\"https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html<\/a>\u00a0Zugriff: April 2020.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Addeo A, et al. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. Front Oncol. 2019 16;9:264.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Planchard D, et al. Metastatic Non-small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology 29(supplement 4): iv192-iv237, 2018.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>\u00ae<\/sup>) for Non-Small Cell Lung Cancer. NCCN Evidence Block<sup>\u2122<\/sup>. Version 1.2020.\u00a0<sup>\u00a9<\/sup>\u00a0National Comprehensive Cancer Network, Inc. 2019. Alle Rechte vorbehalten. Zugriff: April 2020. Um die aktuellste und umfassendste Version der Richtlinien einzusehen, besuchen Sie NCCN.org.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Garassino M, et al. Patient-reported Outcomes Following Pembrolizumab or Placebo Plus Pemetrexed and Platinum in Patients With Previously Untreated, Metastatic, Non-Squamous Non-Small-Cell Lung Cancer (KEYNOTE-189): A Multi Centre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Oncol. 2020 21(3):387-397.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Mazieres J, et al. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 Jan 20;38(3):271-280.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Gandhi L, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:2078 \u2013 2092.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Paz-Ares L, et al; Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Eng J Med 2018;379:2040-2051.    <\/li>\n\n<\/ol>\n\n\n\n<p class=\"has-negative-1-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9339adde3565ad4c26ee0be826ecda23\">Lesen Sie bitte vor dem Verschreiben die vollst\u00e4ndige Fachinformation, die auf der medizinischen Website von Swissmedic (<a href=\"https:\/\/www.swissmedicinfo.ch\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo.ch<\/a>) zur Verf\u00fcgung gestellt wird.<\/p>\n\n\n\n<p class=\"has-negative-1-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--af3682b61c3271bde20798c2a538fd35\">Kopien der Publikationen zu der Studie k\u00f6nnen unter der unten angegebenen Adresse angefordert werden.\u00a9 MSD Merck Sharp &amp; Dohme AG, Werftestrasse 4, 6005 Luzern, Schweiz. Alle Rechte vorbehalten.<a href=\"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/\">Klicken Sie hier f\u00fcr die Fachinformation von KEYTRUDA(Pembrolizumab).<\/a>CH-KEY-00323 | Mai 2020<\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--2baec75282c6a43136157cbf981dfb43\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--f52d3d25a24f7bf239b6531d86bd7547 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Kurzfachinformation KEYTRUDA\u00ae\">\n                    <span class=\"mhh-mcn-v1-link__label\">Kurzfachinformation KEYTRUDA\u00ae<\/span>\n                <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IMMUNTHERAPIEN \u00c4NDERN DIE BEHANDLUNGSPARADIGMEN BEI PATIENTEN MIT FORTGESCHRITTENEM NSCLC Fu\u00dfnoten *Patienten, die nach der platinbasierten Erstlinientherapie aufgrund von neu diagnostiziertem [&hellip;]<\/p>\n","protected":false},"author":385,"featured_media":0,"parent":0,"menu_order":44,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":true,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","primary_tag":0,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["active","is_keyword","is_date"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[715],"tags":[],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[989],"ga4_page_businessunit":[995],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[1208],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[627],"tx-product":[642],"tx-pathology":[],"tx-content-type":[682],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-11546","page","type-page","status-publish","hentry","category-campaign"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Best treatment first - MyMSD.ch DE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Best treatment first - MyMSD.ch DE\" \/>\n<meta property=\"og:description\" content=\"IMMUNTHERAPIEN \u00c4NDERN DIE BEHANDLUNGSPARADIGMEN BEI PATIENTEN MIT FORTGESCHRITTENEM NSCLC Fu\u00dfnoten *Patienten, die nach der platinbasierten Erstlinientherapie aufgrund von neu diagnostiziertem [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch DE\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-24T20:34:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"611\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/\",\"url\":\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/\",\"name\":\"Best treatment first - MyMSD.ch DE\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\",\"datePublished\":\"2021-06-17T14:49:48+00:00\",\"dateModified\":\"2025-11-24T20:34:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#breadcrumb\"},\"inLanguage\":\"de-CH\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-CH\",\"@id\":\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#primaryimage\",\"url\":\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\",\"width\":1500,\"height\":611},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mymsd.ch\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Best treatment first\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mymsd.ch\/de\/#website\",\"url\":\"https:\/\/www.mymsd.ch\/de\/\",\"name\":\"MyMSD.ch DE\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mymsd.ch\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-CH\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mymsd.ch\/de\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\/\/www.mymsd.ch\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-CH\",\"@id\":\"https:\/\/www.mymsd.ch\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png\",\"width\":2186,\"height\":2134,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/de\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Best treatment first - MyMSD.ch DE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/","og_locale":"de_DE","og_type":"article","og_title":"Best treatment first - MyMSD.ch DE","og_description":"IMMUNTHERAPIEN \u00c4NDERN DIE BEHANDLUNGSPARADIGMEN BEI PATIENTEN MIT FORTGESCHRITTENEM NSCLC Fu\u00dfnoten *Patienten, die nach der platinbasierten Erstlinientherapie aufgrund von neu diagnostiziertem [&hellip;]","og_url":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/","og_site_name":"MyMSD.ch DE","article_modified_time":"2025-11-24T20:34:04+00:00","og_image":[{"width":1500,"height":611,"url":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/","url":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/","name":"Best treatment first - MyMSD.ch DE","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#primaryimage"},"image":{"@id":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png","datePublished":"2021-06-17T14:49:48+00:00","dateModified":"2025-11-24T20:34:04+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#breadcrumb"},"inLanguage":"de-CH","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/de\/best-treatment-first\/"]}]},{"@type":"ImageObject","inLanguage":"de-CH","@id":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#primaryimage","url":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png","contentUrl":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png","width":1500,"height":611},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/de\/best-treatment-first\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/de\/"},{"@type":"ListItem","position":2,"name":"Best treatment first"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/de\/#website","url":"https:\/\/www.mymsd.ch\/de\/","name":"MyMSD.ch DE","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-CH"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/de\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-CH","@id":"https:\/\/www.mymsd.ch\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png","contentUrl":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png","width":2186,"height":2134,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/11546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/users\/385"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/comments?post=11546"}],"version-history":[{"count":16,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/11546\/revisions"}],"predecessor-version":[{"id":125947,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/11546\/revisions\/125947"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/media?parent=11546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/categories?post=11546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tags?post=11546"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_audience?post=11546"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_birn_id?post=11546"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_branding?post=11546"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_businessunit?post=11546"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_campaign?post=11546"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=11546"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=11546"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=11546"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_experience?post=11546"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_indication?post=11546"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_material_intent?post=11546"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_product?post=11546"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_region?post=11546"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=11546"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-therapeutic-area?post=11546"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-product?post=11546"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-pathology?post=11546"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-content-type?post=11546"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-active-ingredient?post=11546"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/access?post=11546"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/user_status?post=11546"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/user_role?post=11546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}